A Clinical Study to Evaluate Pancharavinda Choornam for Improving Sleep in People with Insomnia

An open label clinical study to evaluate the efficacy of Pancharavinda Choornam in the management of Insomnia disorder - NIL

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2026/07/113469

Enrollment

Registered

2026-07-06

Start date

Unknown

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: F510- Insomnia not due to a substance orknown physiological condition

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: Diagnosed case of insomnia disorder according to DSM 5 criteria Age group between 20 and 60 years Patients of both genders, irrespective of socioeconomic status

Exclusion criteria

Exclusion criteria: Insomnia due to substance abuse or trauma Physiological conditions such as pregnancy lactation and puerperal stage Subjects with milk allergy

Design outcomes

Primary

Measure	Time frame
Improvement in insomnia severity after treatment with Pancharavinda Choornam, as assessed using Insomnia Severity IndexTimepoint: at baseline, 30 days & 45 days	—

Secondary

Measure	Time frame
Change in overall sleep quality & sleep disturbances from baseline to the end of treatment, as assessed using the Pittsburgh Sleep Quality Index Timepoint: at baseline, 30 days & 45 days;Change in depression, anxiety, & stress scores from baseline to the end of treatment, as assessed using the Depression Anxiety Stress Scale Timepoint: at baseline, 30 days & 45 days;Safety & tolerability of Pancharavinda Choornam, as assessed by the incidence of adverse events & changes in liver function tests & serum creatinine from baseline to the end of treatmentTimepoint: at baseline, 30 days & 45 days	—

Measure

Time frame

Change in overall sleep quality & sleep disturbances from baseline to the end of treatment, as assessed using the Pittsburgh Sleep Quality Index Timepoint: at baseline, 30 days & 45 days;Change in depression, anxiety, & stress scores from baseline to the end of treatment, as assessed using the Depression Anxiety Stress Scale Timepoint: at baseline, 30 days & 45 days;Safety & tolerability of Pancharavinda Choornam, as assessed by the incidence of adverse events & changes in liver function tests & serum creatinine from baseline to the end of treatmentTimepoint: at baseline, 30 days & 45 days

—

Countries

India

Contacts

Public ContactDr Dileep K S

Vaidyaratnam

dileepkshankar@gmail.com9961045901

Outcome results